Aldebaran Capital’s OnKure Therapeutics OKUR Stock Holding History

Aldebaran Capital’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$167K	Sell	40,419 -865	-2%	-$2.67K	0.13%	42
2025 Q4	$120K	Sell	41,284 -2,713	-6%	-$8.12K	0.11%	35
2025 Q3	$121K	Sell	43,997 -176	-0.4%	-$436	0.11%	33
2025 Q2	$106K	Sell	44,173 -875	-2%	-$2.29K	0.1%	34
2025 Q1	$194K	Sell	45,048 -524	-1%	-$2.95K	0.18%	39
2024 Q4	$392K	Buy	45,572 +360	+0.8%	+$5.45K	0.37%	31
2024 Q3	$769K	Buy	45,212 +450	+1%	+$6.66K	0.7%	25
2024 Q2	$676K	Buy	44,762 +5,121	+13%	+$86.8K	0.63%	24
2024 Q1	$658K	Buy	+39,641	New	+$654K	0.63%	23

Other funds holding OKUR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Aldebaran Capital's OKUR Position: Q1 2026 in Review

Aldebaran Capital reduced its OnKure Therapeutics (OKUR) stake by 2.1% in Q1 2026, selling an estimated $2.67K and leaving 40,419 shares worth $167K. The position accounts for 0.13% of the portfolio, ranked #42.

Aldebaran Capital first reported a position in OKUR in Q1 2024 and has held it in 9 quarters since. The position peaked at $769K in Q3 2024. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

Aldebaran Capital held 40,419 shares of OnKure Therapeutics worth $167K as of Q1 2026.
Aldebaran Capital sold 865 OnKure Therapeutics shares in Q1 2026, an estimated $2.67K.
OnKure Therapeutics made up 0.13% of Aldebaran Capital's portfolio in Q1 2026, its #42 holding.
Aldebaran Capital first reported a position in OnKure Therapeutics in Q1 2024 and has held it in 9 quarters since.
Aldebaran Capital's OnKure Therapeutics position peaked at $769K in Q3 2024.
51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Aldebaran Capital's 13F filing for Q1 2026, filed 7 May 2026.